SCHEMBL5377050

SCHEMBL5377050

Cc1ccc(S(=O)(=O)N(c2ccccc2)c2ccc3ncoc3c2)cc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 3/20 0.39
LMNA P02545 3/20 0.38
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ESR1 P03372 1/20 0.37
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PDE10A Q9Y233 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MTOR P42345 1/20 0.35
KDM4E B2RXH2 2/20 0.34
POLB P06746 2/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5921913 0.90 SMN1; SMN2 (0.40) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL5375181 0.80 MAPT (0.46) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL5371938 0.80 TRPM8 (0.39) POLB
SCHEMBL5376611 0.72 SMN1; SMN2 (0.34) SMN1; SMN2NPC1RAB9AALDH1A1MEN1
SCHEMBL5367888 0.72 GAA (0.37) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL5716848 0.71 CASP3 (0.42) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL5382107 0.71 SMN1; SMN2 (0.35) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL5391241 0.71 ALDH1A1 (0.35) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL5374543 0.71 POLB (0.43) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL5921904 0.71 MAPT (0.46) SMN1; SMN2NPC1RAB9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD SMN1; SMN2 3404/4885NPC1 59/4885RAB9A 2271/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD SMN1; SMN2 3296/4885NPC1 74/4885RAB9A 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.